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FGF21, a member of the fibroblast growth factor
(FGF) superfamily, has recently emerged as a regu-
lator of metabolism and energy utilization. However,
the exact mechanism(s) whereby FGF21mediates its
actions have not been elucidated. There is con-
siderable evidence that insulin resistance may arise
from aberrant accumulation of intracellular lipids in
insulin-responsive tissues due to lipotoxicity. In
particular, the sphingolipid ceramide has been impli-
cated in this process. Here, we show that FGF21
rapidly and robustly stimulates adiponectin sec-
retion in rodents while diminishing accumulation
of ceramides in obese animals. Importantly, adipo-
nectin-knockout mice are refractory to changes in
energy expenditure and ceramide-lowering effects
evoked by FGF21 administration. Moreover, FGF21
lowers blood glucose levels and enhances insulin
sensitivity in diabetic Lepob/ob mice and diet-induced
obese (DIO) mice only when adiponectin is function-
ally present. Collectively, these data suggest that
FGF21 is a potent regulator of adiponectin secretion
and that FGF21 critically depends on adiponectin to
exert its glycemic and insulin sensitizing effects.
INTRODUCTION
Fibroblast growth factor 21 (FGF21) has garnered increasing
attention for its abilities to lower blood glucose and circulating
lipid concentrations, and reduce body weight via ameliorated
adiposity (Coskun et al., 2008; Kharitonenkov and Larsen,
2011; Kharitonenkov et al., 2005). Endogenous FGF21 is
induced physiologically by fasting (Adams and Kharitonenkov,
2012) and feeding of ketogenic diets (Badman et al., 2007) or
pharmacologically through the use of PPARa, PPARg, or FXR
agonists, which promote its production in liver and adipose
tissue (Potthoff et al., 2012). Administration of recombinant
FGF21 to cultured cells (Kharitonenkov et al., 2005), rodents
(Berglund et al., 2009; Coskun et al., 2008), and primates (Khar-
itonenkov et al., 2007) improves glucose metabolism. However,790 Cell Metabolism 17, 790–797, May 7, 2013 ª2013 Elsevier Inc.the mechanisms governing the metabolic improvements elicited
by FGF21 are not completely understood.
FGF21, like the other ‘‘endocrine’’ FGF subfamily members
FGF19 and FGF23, binds to its receptor in a heparin-sulfate-
independent manner, a feature that separates these molecules
from the canonical FGFs (Itoh, 2010). In place of heparin,
FGF19 and FGF21 utilize a signaling complex consisting of an
activity competent FGF receptor (FGFR) and the scaffold protein
bKlotho (KLB) (Kharitonenkov et al., 2008). KLB is predominantly
expressed inmetabolically active organs such as adipose tissue,
liver, and pancreas, making these the primary sites of FGF21
action (Adams et al., 2012b). Emerging evidence suggests that
adipose tissue-derived secretory factors are likely to be critical
drivers of the metabolic improvements elicited by FGF21.
Adipose-specific elimination of FGFR1 has been shown to
completely abrogate all of the hypoglycemic, insulin-lowering,
and triglyceride-lowering effects of FGF21 but not FGF19
(Adams et al., 2012c). While complete ablation of KLB abrogates
the entire spectrum of FGF21 activity in vivo (Adams et al.,
2012a), adipose tissue-specific ablation of KLB prevents many,
however not all, of the improvements of FGF21 (Ding et al.,
2012). Collectively, these findings suggest that FGF21 exerts
profound effects on energy expenditure and whole-body
glucose metabolism largely through activation of the FGFR1/
KLB complex in adipose tissue.
Adiponectin (Adn) and leptin are both prominent adipokines
that may facilitate responses to FGF21. Adiponectin potently
opposes hyperglycemia, insulin resistance, inflammation, and
lipotoxic damage (Turer and Scherer, 2012). Here, we address
the role of adiponectin as a potential mediator of the metabolic
effects of FGF21.
RESULTS AND DISCUSSION
To expand upon our recent observation that circulating adipo-
nectin levels are elevated after chronic FGF21 administration
(Adams et al., 2012c), we utilized 3T3-L1 adipocytes to deter-
mine whether the effect could be observed in a cell-autonomous
manner. Modest, albeit significant, increases in adiponectin
were detected from the media of cultured 3T3-L1 adipocytes
after FGF21 treatment (p < 0.05); furthermore, FGF21 potently
prevented tumor necrosis factor-alpha (TNFa) from impairing
adiponectin secretion (Figure 1A). In contrast, incubation of
Figure 1. FGF21 Promotes Adiponectin
Secretion and Diminishes Ceramide Accu-
mulation in Serum
(A) Adiponectin from media conditioned for 2 hr
after L1 adipocytes were cultured for 16 hr with
TNFa (10 ng/ml) or BSA control, in the presence of
FGF21 (100 ng/ml, gray bars) or PBS (black bars).
n = 8 from separate experiments.
(B) Primary murine adipocytes were isolated and
equal aliquots were cultured for 4 hr with the
TZD rosiglitazone (1 mM) or FGF21 (100 ng/ml).
Conditioned media was collected and subjected
to SDS-PAGE, and western blots were performed
with antibodies to adiponectin (aAdn). Data are
representative of five independent experiments
from separate animals.
(C) Serum adiponectin was measured from sera
collected at the indicated time points after
injection of FGF21 (1 mg/kg, intraperitoneal) into
WT mice.
(D) WT mice were injected with indicated doses of
human FGF21. Adiponectin was measured by
ELISA on serum samples obtained before or after
FGF21 treatment, and the change in adiponectin
was calculated (n = 5–6 per group).
(E) HMW (black bars), LMW (gray bars), and
trimeric (hatched bars) adiponectin fromWTmice,
WT mice 2 hr after FGF21 treatment (1 mg/kg,
intraperitoneal), or transgenic (Tg) FGF21 over-
expressing mice (n = 5/group).
(F) Plasma ceramides from WT, FGF21-over-
expressing mice, and FGF21-knockout mice
(n = 5/group).
(G) Plasma ceramides from lean (white bars) or
DIO mice after treatment with vehicle (black bars),
FGF21 (1 mg/kg/day, gray bars), or rosiglitazone
(10 mg/kg/day, hatched bars) (n = 5/group).
Results are shown as mean ± SEM. Asterisks
indicate p < 0.05 for FGF21 effects. The dagger
denotes p < 0.05 for TNFa effect. See also
Figure S1.
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FGF21 and AdiponectinFGF21 with primary murine adipocytes strongly upregulated
adiponectin secretion into medium and was even more potent
than the PPARg agonist rosiglitazone (Figure 1B). We further
evaluated the kinetics required for a single bolus of FGF21 to
increase circulating adiponectin levels in vivo. We were sur-
prised to discover that adiponectin levels began to rise within
5 min of treatment and were significantly elevated within
15 min (Figure 1C). Increased levels persisted for at least 2 hr
after acute treatment with FGF21 and remained 2.76-fold higher
(p < 0.05) than those in vehicle-treated mice after 2 weeks of
FGF21 administration, through continuous subcutaneous infu-
sion via osmotic minipumps (Figure S1A available online).
Dose-response studies were performed with a single bolus
injection of FGF21 (Figure 1D), which produced significant in-
creases in serum adiponectin with as little as a 46% increase
in circulating FGF21 (Figure S1B). Thus, recombinant FGF21
can stimulate a rapid, robust, and prolonged release of adipo-
nectin both in vitro in cultured adipocytes and in vivo in rodents.
Adiponectin is an adipocyte derived protein known to circulate
in a combination of three forms: trimers, low-molecular-weight
(LMW) multimers, and high-molecular-weight (HMW) oligomers.
Adiponectin expression is enhanced by PPARg agonists and isCessential for these agonists to reach their optimal antidiabetic
effects (Kubota et al., 2006; Nawrocki et al., 2006). The HMW
form of the protein is the best biomarker for clinical efficacy of
thiazolidinediones (TZDs) (Combs et al., 2002). Although our
FGF21-transgenic mice (Kharitonenkov et al., 2005) only show
a 10% increase in total circulating adiponectin (p < 0.05), they
exhibit more striking elevation of HMW adiponectin levels,
whereas in wild-type (WT) animals, administration of recombi-
nant FGF21 increases both HMW and LMW adiponectin (Fig-
ure 1E). These findings corroborate recent reports that adipo-
nectin is elevated in FGF21-transgenic mice from other groups
(Dinget al., 2012).Whencompared toWTmice, our FGF21/an-
imals (Badman et al., 2007) on a high-fat diet show significantly
impaired adiponectin production (3.71 ± 0.26 mg/ml versus
2.15 ± 0.19 mg/ml, p < 0.05). Thus, FGF21 is likely critical for
maintaining basal adiponectin levels, particularly during obesity.
Our previous work suggests that adiponectin exerts its
numerous biological effects, in part, by enhancing the deacyla-
tion of the sphingolipid ceramide, a lipotoxic metabolite stimu-
lated primarily by excess exposure to saturated fats or inflamma-
tory mediators (Holland et al., 2011). With adiponectin potentially
playing a critical role in FGF21-mediated glucose-loweringell Metabolism 17, 790–797, May 7, 2013 ª2013 Elsevier Inc. 791
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FGF21 and Adiponectineffects, we subsequently evaluated circulating ceramide levels in
FGF21-transgenic and -knockout mice, which have been
described previously (Kharitonenkov et al., 2005; Badman
et al., 2007). FGF21-overexpressing mice display lower concen-
trations of circulating ceramide, whereas FGF21-knockout
animals display mild but significant (p < 0.05) increases in circu-
lating ceramide levels (Figure 1F).
Consistent with the results obtained with genetic mouse
models, circulating ceramide levels were diminished in WT
mice after treatment with recombinant FGF21 in a time-depen-
dent manner (Figure 1G). Circulating ceramide concentrations
were approximately twice as high in diet-induced obese (DIO)
mice and remained unchanged by vehicle treatment. Three
days of FGF21 administration to DIO mice significantly
decreased ceramide levels (p < 0.05), and they were completely
normalized after 2 weeks of treatment. The PPARg agonist
rosiglitazone is a known stimulator of FGF21 production and
adiponectin secretion. We and others have previously estab-
lished adiponectin secretion (Kubota et al., 2006; Nawrocki
et al., 2006) is essential for normal antidiabetic responses to
TZDs. It has been recently demonstrated that FGF21/ mice
fail to exhibit the antiglycemic effects of TZD treatment, a defect
linked to blunted adiponectin production (Dutchak et al., 2012);
however, another FGF21-knockout line utilized in this study
(Badman et al., 2007) maintains a normal response to TZD
administration (A.C.A. and A.K., unpublished data). We show
here that rosiglitazone effectively achieved ceramide lowering
after 7 and 14 days of treatment. These data suggest that
FGF21 abates ceramide accumulation, which is a key biomarker
of adiponectin action. All together, these data suggest that
FGF21, adiponectin, and ceramides may lie in a collinear
pathway, with TZDs evoking important, yet unresolved, roles
in this process.
We find dramatic effects of FGF21 on adiponectin production
and release, both acutely and in the chronic setting. Effects of
such magnitude on adiponectin secretion have not been
observed previously. It is difficult to induce acute enhancements
of adiponectin release in adipocytes, and the effects reported in
the chronic setting are on par with the fold stimulation for pro-
longed TZD treatment (Nawrocki et al., 2006). We and others
have demonstrated that adiponectin is essential for the full
metabolic improvements induced by TZDs, as Adn/ mice
show minimal improvements to standard doses of rosiglitazone
(Kubota et al., 2006; Nawrocki et al., 2006).
Prior to embarking on studies with adiponectin null mice, we
sought to ensure that Adn/ mice have all components of the
FGF21-specific receptor machinery, FGFRs and KLB, and
exhibit a normal signaling response to FGF21 (Kharitonenkov
and Larsen, 2011). Expression of all four major FGF receptors
and KLB was not significantly altered in liver or adipose by
adiponectin ablation (Figure S2A). Furthermore, FGF21-induced
transcription of the immediate early genes early growth response
protein 1 (EGR1) (Figures S2B and S2) and cFos (Figures S2D
and S2E) remained intact in adipose and liver of Adn/ mice.
Finally, FGF21 levels are normal during fed and fasted states in
Adn/ mice (Figure S3). Thus, Adn/ mice maintain essential
components of FGF21 signaling in both adipose and liver and
are able to respond in a normal acute fashion to FGF21 adminis-
tration at the signaling level.792 Cell Metabolism 17, 790–797, May 7, 2013 ª2013 Elsevier Inc.To evaluate the role of adiponectin in FGF21-mediated meta-
bolic improvements, we treated WT or Adn/ mice chronically
with FGF21 via osmotic minipumps after they were maintained
on a high-fat diet for 6 weeks to promote diet-induced obesity.
FGF21 treatment produced similar elevations in circulating
FGF21 (25.22 ± 2.97ng/ml in WT mice and 24.26 ± 4.63 ng/ml
in Adn/ mice). Consistent with the established effects of
FGF21 on energy expenditure (Coskun et al., 2008), WT mice
receiving FGF21 display potent decreases in body weight (Fig-
ure 2A). Although FGF21 still promoted weight loss in Adn/
mice, they lost significantly less body weight than did WT mice
(p < 0.01). Nuclear magnetic resonance (NMR) analysis of body
composition revealed a 39% reduction of fat mass in WT mice
(p < 0.005), whereas Adn/ mice only lost 6.7% (p = 0.52) of
their fat mass during the first week of FGF21 treatment (data
not shown). Analysis of glucose levels during chronic administra-
tion of FGF21 revealed a substantial lowering of serum glucose
only in WT mice (Figure 2B), with a complete failure to lower
blood glucose in Adn/ mice.
Identically treated cohorts were evaluated in metabolic cages
from days 2–6 after implantation of minipumps to determine
energy expenditure effects. In response to FGF21, WT mice
displayed the expected decreases in respiratory exchange ratio
(RER) (Figure 2C) and increases in energy expenditure, as
measured by oxygen (O2) consumption (Figure 2D) and carbon
dioxide (CO2) production (Figure 2E). The downward shift in
RER, reflecting a slight increase in lipid oxidation for energy pro-
duction, was not evident in Adn/ mice. Moreover, Adn/
animals were partially refractory to increases in energy expendi-
ture; however, their responsiveness was completely dependent
on the light cycle. Although O2 consumption and CO2 production
were fully enhanced by FGF21 at night (p < 0.05), energy expen-
diture was not elevated during the light phase or on average
throughout the entire day in Adn/ mice.
We additionally analyzed profiles of several circulating lipid
classes (Figure 2F). Importantly, various anticipated effects of
FGF21 on serum lipids occurred independently of adipo-
nectin. FGF21 promoted the expected decreases in circulating
triglyceride (TG) and cholesterol (CHO) in serum of either genetic
group. The ketone b-hydroxybutyrate was elevated by FGF21 in
both groups. Serum ceramides were diminished after 2 weeks of
FGF21 treatment in WT mice (p < 0.05, Table S1); however,
ceramides were not significantly altered in adiponectin deficient
mice (p < 0.19). For this study, serum ceramides only showed
trends toward elevation in Adn/ mice, unlike what we saw in
other studies (Figure 3) (Holland et al., 2011). This is likely due
to the surgical manipulations with the minipumps that led to a
slight temporary weight loss.
Body mass was still significantly decreased in Adn/ mice,
which could account for the trend toward the decrease in
ceramides in Adn/ mice. Such changes in body weight also
obscure interpretations of insulin sensitivity tests, as body
mass profoundly effects insulin sensitivity. Given these limita-
tions, we opted to analyze insulin action after acute adminis-
tration of FGF21, which prevents the confounding effect of
differences in body weight. To evaluate insulin sensitivity, we
performed hyperinsulinemic-euglycemic clamps on con-
scious unrestrained WT or Adn/ mice. Intravenous infusion
of FGF21 into wild-type DIO mice substantially improved
Figure 2. Adiponectin Critically Regulates
Improvements in Glucose Homeostasis,
but Not BodyWeight Regulation in DIOMice
(A and B) Body weight (A) and blood glucose
(B) from WT (squares) or adiponectin-knockout
(triangles) mice treated with FGF21 (0.3 mg/
kg/day, open shapes/dashed lines) or PBS (filled
shapes/solid lines) (n = 8/group).
(C) Average RER during the night from WT and
Adn/ mice treated with PBS (black) or FGF21
(gray).
(D and E) Oxygen consumption (D) and carbon
dioxide production (E) from WT (squares) or
Adn/ mice (triangles) treated with FGF21
(0.3 mg/kg/day, open shapes/dashed lines) or
PBS (filled shapes/solid lines) (n = 8/group).
(F) Serum lipid concentrations were determined
and expressed as a percentage of the PBS/WT
controls (control values: 80.67 ± 8.88 mg/dl
triglyceride [TG], 160.16 ± 5.49 mg/dl cholesterol
[CHO], 4.20 ± 0.17 mg/dl b-hydroxybutyrate
[b-HB], 1.64 ± 0.15 mg/ml ceramides) after treat-
ments with FGF21 (0.3 mg/kg/day, gray) or PBS
(black) by minipump (n = 6 per group).
Results are mean ± SEM. Asterisks indicate
p < 0.05 for FGF21 effects. The dagger denotes
p < 0.05 for Adn/ versus WT of same treatment.
See also Figures S2 and S3 and Table S1.
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FGF21 and Adiponectinwhole-body insulin sensitivity, as measured by the amount of
glucose required to maintain euglycemia (Figure 3A). Serum
adiponectin concentrations doubled (p < 0.05) in response to
FGF21- (18.85 ± 3.08 mg/ml) as compared to PBS-infused
(9.75 ± 1.60 mg/ml) wild-type mice. Consistent with our estab-
lished clamp data from adiponectin transgenic studies (Combs
et al., 2001; Holland et al., 2011) and previous clamp experi-
ments with FGF21 infusions (Berglund et al., 2009), all of the
improvements could be accounted for by suppression of
hepatic glucose efflux (Figure 3B). FGF21 failed to improve insu-
lin action in DIO Adn/ mice on the whole body or the liver.
These results could not be explained by differences in circu-
lating hFGF21 levels (21.98 ± 0.35 ng/ml in WT mice and
20.72 ± 0.73 ng/ml in Adn/ mice), blood glucose, or serum
insulin in the clamped state. To evaluate lipid intermediates
linked with insulin resistance, we assessed TG, diacylglycerol
(DAG), and ceramide levels from livers obtained from these
acute FGF21 experiments (Figure 3C). While TG and DAG
were not significantly altered by this short treatment withCell Metabolism 17, 790FGF21, hepatic ceramides were sig-
nificantly lower in WT mice. Adipo-
nectin-null mice did not display the
same FGF21-induced effects on hepatic
ceramides.
To assess insulin signaling in this acute
setting, we harvested tissues 15 min after
initiating clamps in a separate cohort of
animals. We evaluated insulin-stimulated
PI3 kinase activity and Akt (PKB) kinase
phosphorylation, two essential compo-
nents of insulin signal transduction (Fig-
ures 3D–3F). In cultured cells, ceramidesimpair insulin signaling to Akt, while PI3 kinase activation re-
mains intact. Consistent with these findings, FGF21 enhanced
insulin-stimulated phosphorylation of Akt in the liver of WT
mice, but not Adn/ mice. Insulin-stimulated activation of
IRS2-associated PI3 kinase activation was not enhanced by
FGF21 in either genetic group. Changes in ceramide species (Ta-
ble S1) were consistent with previous changes noted to correlate
with insulin sensitivity in adiponectin transgenic mice and in hu-
man studies (Haus et al., 2009; Holland et al., 2011; Lopez et al.,
2013). Collectively, these data from DIO mice suggest that
FGF21 promotes improvements in hepatic glucose output and
whole-body glucose homeostasis via mechanisms that require
adiponectin. However, changes in energy expenditure and
body mass are partially independent of adiponectin and vary
greatly with circadian rhythms.
Although leptin deficiency promotes elevation in circulating
FGF21 levels, Lepob/ob mice maintain exquisite sensitivity to
the glucose-lowering effects of recombinant FGF21. Our data
suggest that at the low doses utilized for our chronic studies–797, May 7, 2013 ª2013 Elsevier Inc. 793
Figure 3. Adiponectin Is Essential for Enhanced Insulin Action after
Acute Administration of FGF21
After 6 weeks of high-fat diet, WT and Adn/mice received chronic indwelling
jugular catheters and were allowed to recover to presurgical weight. FGF21
(1 mg/kg/min, intravenous, gray bars) or PBS (black bars) was infused for
90 min prior to initiation of hyperinsulinemia and throughout the duration of the
experiment (n = 4–5 per group).
(A and B) Hyperinsulinemic-euglycemic clamps were performed on conscious
unrestrained mice. The glucose infusion rate required to maintain euglycemia
was determined (A) and the rate of glucose efflux from the liver was calculated
from kinetic measurements of 3H-glucose turnover (B).
(C) Lipids were extracted from livers obtained from mice after experiments,
and triglyceride (TG), diacylglycerol (DAG), and ceramide concentrations were
quantified and expressed as a percentage of the PBS/WT controls (control
values: 108.4 ± 25.3 mg/g TG, 867.7 ± 168.0 nmol/g DAG, 172.0 ± 7.8 nmol/g
ceramide).
(D–F) Hyperinsulinemic clamps were initiated for 15 min, and tissues were
snap frozen for analysis of insulin signaling intermediates.
(D) Representative samples of 32P-labeled 3,4,5-trisphosphoinositol [PI(3)P]
from IRS2-associated PI3 kinase assays (E), and immunoblots against phos-
phorylated (serine 473) Akt and total Akt1 (F).
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794 Cell Metabolism 17, 790–797, May 7, 2013 ª2013 Elsevier Inc.(0.3 mg/kg/day), FGF21 does not cause significant decreases in
body weight in Lepob/ob mice, consistent with previous reports in
this strain (Figure 4A) (Adams et al., 2012b). Despite the lack of
change in body weight in Lepob/ob mice, they still display robust
improvements in blood glucose concentrations in response to
FGF21 (Figure 4B). To gauge the contribution of adiponectin to
FGF21-mediated improvements in glucose homeostasis in a
diabetic model, we subsequently crossed our Adn/ mice
with Lepob/ob mice on an FVB genetic background. These
leptin/adiponectin double-knockout (DKO) mice showed similar
blood glucose concentrations and similar fasted FGF21 levels to
Lepob/ob mice prior to treatments (Figure S3B). FGF21 levels
were higher in DKO mice during the fed state. As with leptin-
only knockouts, FGF21 did not promote significant weight loss
in DKO mice. Unlike Lepob/ob mice, DKOs were completely
refractory to the improvements in blood glucose caused by
FGF21 (Figure 4B).
Adiponectin secretion is repressed in the context of obesity.
However, upon further elevation of FGF21 with intravenous
infusion into Lepob/ob mice, circulating adiponectin concentra-
tions were significantly increased (4.53 ± 0.89 mg/ml for PBS
and 12.27 ± 1.77 mg/ml for FGF21, p < 0.01). This substantially
improved whole-body insulin sensitivity, as measured by the
amount of glucose required to maintain euglycemia (Figure 4C);
all of the improvements could be accounted for by suppression
of hepatic glucose efflux (Figure 4D). Strikingly, FGF21
completely failed to improve measures of whole-body or hepatic
insulin sensitivity in DKO mice, although similar levels of FGF21
(22.09 ± 0.27 ng/ml for Lepob/ob mice and 22.29 ± 0.35 ng/ml
for DKO mice) were achieved in the circulation of both genetic
groups infusedwith FGF21. These results could not be explained
by differences in blood glucose or serum insulin in the clamped
state. As a measure of adiponectin action, we measured hepatic
ceramides after 10 days of FGF21 treatment (Figure 4E). Ceram-
ides were significantly lowered in the liver by FGF21 in Lepob/ob
mice, but not in DKOmice.We alsomeasured hepatic lipids after
acute FGF21 treatments (Figure 4F). These 3 hr FGF21 infusions
were sufficient to lower hepatic ceramides; however, triglyceride
and diacylglycerol were not significantly affected. While it is
curious that adiponectin secretion and FGF21 levels are dis-
sociated in obesity, we think this is yet another example of
hormonal resistance that occurs during metabolic dysfunction
due to combinations of hypoxia, endoplasmic reticulum stress,
and inflammation.
Collectively, these data from Lepob/ob mice suggest that
adiponectin is essential for FGF21 to enhance suppression of
hepatic glucose efflux and promotewhole-body glucose homeo-
stasis. The results from clamps in Lepob/ob mice and DIO mice
are consistent with previous studies with adiponectin alterations.
Hyperinsulinemic clamps in Adn-transgenic mice (Combs et al.,
2004), Adn/ mice (Nawrocki et al., 2006), or wild-type mice(E) Insulin-stimulated activation of IRS2-associated PI3 kinase activity was
quantified and graphed as fold stimulation over non-insulin-treated samples.
(F) Insulin-stimulated phosphorylation of Akt kinase was quantified and
normalized to total Akt. Data are graphed as fold stimulation over non-insulin-
treated samples.
Results are mean ± SEM. Asterisks indicate p < 0.05 for FGF21 effects. The
dagger denotes p < 0.05 for Adn/ versus WT of same treatment.
Figure 4. Adiponectin Critically Regulates
Improvements in Glucose Homeostasis in
Lepob/ob Mice
(A and B) Changes in body weight (A) and
blood glucose (B) during infusion of FGF21
(0.3 mg/kg/day, dashed lines, open shapes) or
PBS (solid lines, filled shapes) by subcutaneous
minipumps into Lepob/ob mice (squares) or
Lepob/ob-Adn/ mice (DKO, triangles) (n = 4/
group).
(C and D) Hyperinsulinemic euglycemic clamps
were performed during acute infusion of FGF21
(1 mg/kg/min, intravenous, gray bars) or PBS
(black bars). The glucose infusion rate required to
maintain euglycemia (C) and the rate of glucose
efflux from the liver (D) were determined. (n = 4/
group).
(E) Liver ceramide content after a 10 day treatment
with FGF21 (gray bars) or PBS (black bars).
(F) Lipids were extracted from livers obtained from
mice after acute administration of FGF21 (clamp
experiments), and triglyceride (TG), diacylglycerol
(DAG), and ceramide concentrations were quan-
tified and expressed as a percentage of the PBS/
Lepob/ob controls (control values: 100.8 ± 2.8 mg/g
TG, 1347.9 ± 192.8 nmol/g DAG, 174.6 ±
10.7 nmol/g ceramide) (n = 4/group).
Results are mean ± SEM. Asterisks indicate
p < 0.05 for FGF21 effects.
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FGF21 and Adiponectintreated with full-length Adn (Holland et al., 2011) uniformly sug-
gest the liver as the primary site of enhanced insulin action
evoked by the intact protein. Similarly, recombinant FGF21 has
been show to aid in the opposition of glucose efflux in Lepob/ob
(Berglund et al., 2009), lean (Xu et al., 2009), or DIO (Xu et al.,
2009) mice.
In summary, we report data that strongly suggest that
enhanced secretion of adiponectin is critical in facilitating
many of the metabolic improvements elicited by FGF21,
including FGF21-mediated effects on ceramide metabolism
that we demonstrate here.EXPERIMENTAL PROCEDURES
Animal Care
Mice were maintained on a 12 hr dark/light cycle and fed a normal chow diet.
Unless otherwise indicated, all mice were 14–16 weeks old at the time of
experiments. Mice were bred in house in the University of Texas Southwestern
Medical Center and Eli Lilly and Company animal facilities. The high-fat diet
consisted of 60% (kCal) from fat (Research Diets, D12492). Lepob/ob mice
were on an FVB background to allow for uniform development of hypergly-
cemia; all other mice were on C57Bl6/J backgrounds. The Institutional Animal
Care and Use Committee of the University of Texas Southwestern MedicalCell Metabolism 17, 790Center and the Eli Lilly and Company approved
all animal experimental protocols.
Animal Surgery
Anesthesia was accomplished by 2% isofluorane.
For clamps, silicone catheters were aseptically
placed in the jugular vein. Rimadyl (5 mg/kg, sub-
cutaneous) was administered for pain control, and
animals were allowed to recover (4–5 days) to
preoperative weight prior to experiments. For
chronic infusions, Alzet osmotic minipumps wereasceptically filled, primed, and asceptically placed subcutaneously in the
midback area.
Hyperinsulinemic-Euglycemic Clamps
Clamps were performed in conscious unrestrained animals as previously
described (Berglund et al., 2009, 2012; Holland et al., 2011). Clamps in DIO
mice were initiated by primed continuous infusion of insulin (4 mU/kg/min),
and glucose wasmaintained constant at150mg/dl during the clamped state
via variable infusion of dextrose (50%). Clamps in Lepob/ob mice were initiated
by primed continuous infusion of insulin (10 mU/kg/min), and glucose was
maintained constant at 250 mg/dl during the clamped state. FGF21 or
PBS was initiated with the onset of 3H-glucose tracer infusion (5 mCi bolus +
0.05 mCi/min) to allow for a 90 min pretreatment. Continuous infusion of
FGF21 was maintained after initiation of insulin. [3-3H]glucose was increased
to 0.1 mCi/min at the onset of insulin delivery to account for changes in specific
activity. Glucose turnover was determined and hepatic glucose output was
calculated as whole-body glucose disposal less glucose infusion rate as pre-
viously described (Hill et al., 2010). For generation of samples for the analysis
of insulin signaling intermediates, FGF21 or PBS was infused identically, and
insulin stimulation was allowed to proceed for 15 min prior to sacrifice and
rapid freezing of tissues.
Energy Expenditure
Metabolic measurements were obtained continuously with TSE metabolic
chambers (TSE Labmaster System, Germany) in an open-circuit indirect–797, May 7, 2013 ª2013 Elsevier Inc. 795
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FGF21 and Adiponectincalorimetry system. Studies were performed from days 4–6 after implantation
of osmotic pumps. Data were normalized to lean body mass as determined
with a Bruker MQ10 NMR analyzer.
Lipid and Analyte Quantification
Sphingolipid were quantified as described previously by liquid
chromatography/electrospray ionization/tandem mass spectrometry with a
TSQ Quantum Ultra Triple Stage Quadrupole Mass Spectrometer (Thermo
Fisher) equipped with an electrospray ionization probe and interfaced with
an Agilent 1100 HPLC (Agilent Technologies) (Holland et al., 2011; Li et al.,
2009). Glucose wasmeasured by Alpha Trak glucometer (Abbott Labs). Insulin
and adiponectin were quantified by ELISA (Millipore). Adiponectin distribution
was measured as previously described (Schraw et al., 2008). So that con-
tamination of MS equipment with 3H-containing samples could be prevented,
ceramides and diacyglycerols were measured on samples obtained after
hyperinsulinemic-euglycemic clamps via established enzymatic methods
(Perry et al., 2000).
Analysis of Insulin Signaling Intermediates
PI3 kinase assays were performed after immunoprecipitation with antibodies
against IRS2 (Cell Signaling, L1326) and were carried out as previously
described (Wang and Summers, 2003). Immunoblotting for pAkt (Ser473,
4060) and total Akt (2920) (Cell Signaling Technology) was performed as
previously described (Kusminski et al., 2012).
Statistics
The results are shown as mean ± SEM. All statistical analysis was performed
in SigmaStat 2.03 (SysStat Software, Point Richmont, CA). Differences
between multiple groups were determined by two-way ANOVA. Kaplan Meier
plots were compared by log-rank test. For comparison between two
independent groups, the Student’s t test was used. Significance was as
accepted at p < 0.05.
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